• About
  • Services
  • Clients
  • Client News
  • PCG Research
  • PCG Digital
  • Contact
  • follow:

  • 9 Nov

    Oncocyte Reports Third Quarter 2023 Financial Results

    -Launching First Products in 1H 2024- -Conference Call on Thursday, November 9, 2023 at 5:00 a.m. PT / 8:00 a.m. ET- IRVINE, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today reported financial results for the third quarter of 2023, ended September 30, 2023. Third… Read More..

    Share this:
  • 9 Nov

    Nephros Announces Results for Quarter Ended September 30, 2023

    Third-Quarter Net Revenue of $3.7 Million, a 55% Increase Over 2022; Net Loss from Continuing Operations Narrows 85% to $0.2 Million; $1.1 Million in Positive Year-to-Date Net Cash Flows from Operating Activities SOUTH ORANGE, NJ, Nov. 08, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Nephros, Inc. (Nasdaq: NEPH), a leading… Read More..

    Share this:
  • 8 Nov

    Aclarion Announces Achievement of Goal to Enroll 10 Leading Spine Surgery Key Opinion Leaders (KOLs) to Support Nociscan Adoption

    Recruitment of a panel of leading KOL surgeons who believe Nociscan can improve the diagnosis and treatment of discogenic low back pain is a critical step to establishing Nociscan as standard of care. Aclarion’s KOL panel represents spine surgeons at some of the largest and most influential academic centers and… Read More..

    Share this:
« Previous 1 … 126 127 128 129 130 … 243 Next »
  • Twitter feed is not available at the moment.
  • QUICK LINKS

    • About
    • Services
    • Clients
    • Client Media
    • PCG Media
    • PCG Research
    • Contact
    • Privacy Policy
    • Disclosures

    FOLLOW US

    Copyright © 2022 PCG Advisory.

    MENU logo
    • About
    • Services
    • Clients
    • Client News
    • PCG Research
    • PCG Digital
    • Contact